TherapyPrimes v. 3M & KCI: NPWT Patent Suit Dismissed With Prejudice in 92 Days
TherapyPrimes LLC filed suit against 3M Co. and KCI USA Inc. in the Western District of Texas, asserting two patents covering negative pressure wound therapy systems against the 3M Snap Therapy System. The case was dismissed with prejudice after just 92 days — a timeline suggesting a rapid resolution, most likely a private settlement or licensing agreement, before substantive litigation commenced.
NPWT patent clash ends swiftly as TherapyPrimes exits with prejudice
On 9 September 2024, TherapyPrimes LLC filed a patent infringement action in the Western District of Texas (Case No. 6:24-cv-00462) before Judge Kathleen Cardone, asserting US8512301B2 and US9339595B2 against 3M Co. and its wound care subsidiary KCI USA Inc. The accused product was the 3M Snap Therapy System, a compact negative pressure wound therapy (NPWT) device used in clinical and home-care settings.
The case closed on 10 December 2024 — just 92 days after filing — when TherapyPrimes filed a Notice of Dismissal with Prejudice under Federal Rule of Civil Procedure 41(a). Judge Cardone entered an order confirming all claims were dismissed with prejudice, meaning TherapyPrimes is permanently barred from re-asserting the same claims against the same defendants in future proceedings.
A dismissal with prejudice filed this early in litigation — before any substantive motions or claim construction — typically signals that the parties reached a private resolution, such as a licensing agreement or lump-sum settlement. The public record does not disclose financial terms or whether a licence was granted. The speed of resolution, combined with the involvement of KCI USA as a co-defendant, suggests 3M’s legal resources may have accelerated negotiations considerably.
Filing to Dismissed with Prejudice in 92 days
92 days — well below the median district court patent case duration of 2–3 years
Dismissed with prejudice: what the Rule 41 order means for both parties
Rule 41(a) dismissal with prejudice forecloses future claims
Under Federal Rule of Civil Procedure 41(a), a plaintiff may voluntarily dismiss an action. When dismissed ‘with prejudice,’ the dismissal operates as a final adjudication on the merits — TherapyPrimes cannot refile these specific patent claims against 3M or KCI USA in any federal court. This is a permanent procedural bar, not merely a pause in litigation.
Permanent bar on refilingTherapyPrimes permanently surrenders its claims against 3M and KCI
By accepting dismissal with prejudice, TherapyPrimes gave up the right to litigate these patents against 3M and KCI USA forever. This is a meaningful concession — unless offset by a confidential licensing fee or settlement payment. The public record does not disclose any financial consideration, but early voluntary dismissals with prejudice are strongly consistent with a negotiated resolution having been reached.
Claims extinguished — terms undisclosed3M and KCI secured permanent resolution in under three months
For 3M Co. and KCI USA, the dismissal with prejudice delivers maximum procedural certainty: TherapyPrimes cannot revive these claims. Whether that certainty came via settlement payment, a licensing arrangement, or litigation pressure from 3M’s legal team is not publicly known. The outcome removes the NPWT patent cloud over the 3M Snap Therapy System from this plaintiff.
No further exposure to these claimsSwift closure limits market disruption but leaves IP questions open
The rapid closure of this case means no claim construction, no invalidity ruling, and no public adjudication of the patents’ scope. US8512301B2 and US9339595B2 remain valid and enforceable on their face. TherapyPrimes could theoretically assert these patents against other NPWT competitors — the preclusion applies only to 3M and KCI USA, not to the industry at large.
Patents remain enforceable vs. third partiesFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | TherapyPrimes LLC | Company | Medical device IP licensing entity — holder of US8512301B2 and US9339595B2Search in Eureka ↗ |
| Defendant | 3M Co. | Company | 3M Co. and KCI USA Inc. — global medical technology and wound care companiesSearch in Eureka ↗ |
| Co-Defendant | KCI USA, Inc. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Robert D. Katz | Attorney | Counsel for TherapyPrimes LLCSearch in Eureka ↗ |
| Plaintiff law firm | Katz P LLC | Law Firm | Representing TherapyPrimes LLCSearch in Eureka ↗ |
| Presiding judge | Judge Kathleen Cardone | Judge | Texas Western District CourtSearch in Eureka ↗ |
Official order — verbatim text
The Court’s order confirms dismissal of all claims with prejudice pursuant to Rule 41(a), acting on TherapyPrimes’ own Notice of Dismissal. The phrase ‘all claims’ is comprehensive — no carve-outs, partial survivals, or counterclaims are referenced, suggesting defendants had not yet filed responsive pleadings raising counterclaims at the time of dismissal. The with-prejudice designation is the critical operative term: it transforms a voluntary exit into a permanent bar, carrying the legal weight of a final judgment on the merits for preclusion purposes.
US8512301B2 & US9339595B2 — Negative Pressure Wound Therapy Systems
US8512301B2 (application no. US10/906199) and US9339595B2 (application no. US13/958557) both relate to negative pressure wound therapy — a clinical technique that applies sub-atmospheric pressure to a wound site to promote healing, reduce oedema, and manage exudate. These patents cover systems and methods in that therapeutic space. The earlier application number (906199 series) suggests foundational priority dating, while the 958557 application represents a continuation or development of the technology platform.
NPWT is a high-value segment within advanced wound care, dominated commercially by a small number of players including 3M/KCI, Smith+Nephew, and Mölnlycke. Patents covering device architecture, therapy delivery mechanisms, or system configurations in this space carry significant commercial leverage. The assertion of both patents against the flagship 3M Snap Therapy System — a portable, disposable NPWT product — indicates TherapyPrimes believed its claims read on core product functionality, making these patents strategically material for any competitor active in compact or mechanical NPWT devices.
Should your NPWT product team run an FTO against US8512301B2 and US9339595B2?
Any company developing, manufacturing, or distributing negative pressure wound therapy systems — particularly compact, portable, or single-use NPWT devices — should assess freedom-to-operate against these two patents. The 3M Snap Therapy System was specifically named as an accused product, suggesting the claims may be drafted broadly enough to capture modern mechanical NPWT architectures. With these patents remaining valid and enforceable, and TherapyPrimes free to assert them against parties other than 3M and KCI, the exposure is real.
PatSnap Eureka’s FTO Search Agent can map the claim scope of US8512301B2 and US9339595B2 against your product specifications, identify prior art that may bear on validity, and surface related continuation or family patents that could extend the risk perimeter. For R&D teams designing next-generation NPWT devices, running this analysis before product launch is considerably less costly than defending a patent suit in W.D. Texas.
Run a freedom-to-operate analysis on US8512301B2 to assess your product’s exposure
Run FTO in Eureka →Similar NPWT and wound care patent cases in W.D. Texas and beyond
Explore related negative pressure wound therapy patent infringement cases filed in W.D. Texas and other key patent litigation venues targeting wound care technology.
What this case signals for the NPWT and wound care IP landscape
A 92-day dismissal with prejudice in a multi-defendant NPWT patent case carries clear signals for IP teams in the wound care sector.
NPWT patents remain a live enforcement vector beyond this case
The dismissal with prejudice extinguishes TherapyPrimes’ claims only against 3M and KCI USA. US8512301B2 and US9339595B2 remain active and could be asserted against other negative pressure wound therapy system manufacturers. Companies marketing competing NPWT products should treat this case as a signal to review their FTO posture against both patents.
Western District of Texas continues to attract early-stage patent assertions
The choice of W.D. Texas, a historically plaintiff-friendly forum for patent cases, is consistent with a litigation strategy designed to apply commercial pressure. The rapid resolution here suggests defendants with strong resources can convert that pressure into a swift exit — but smaller NPWT manufacturers may face a different dynamic if targeted.
TherapyPrimes v 3M — key questions answered
TherapyPrimes LLC filed a patent infringement suit against 3M Co. and KCI USA Inc. in the Western District of Texas on 9 September 2024, asserting US8512301B2 and US9339595B2 against the 3M Snap Therapy System. The case was dismissed with prejudice on 10 December 2024 — 92 days after filing — following TherapyPrimes’ own Notice of Dismissal under Rule 41(a). No financial terms were publicly disclosed.
The dismissal with prejudice means TherapyPrimes is permanently barred from asserting the same claims against 3M and KCI USA. However, the patents themselves remain valid and enforceable. TherapyPrimes retains the right to assert US8512301B2 and US9339595B2 against other NPWT manufacturers or distributors who were not parties to this case.
A voluntary dismissal with prejudice filed within 92 days — before claim construction or substantive motions — is strongly consistent with a negotiated resolution such as a licensing agreement or settlement payment. The public docket does not disclose terms. The presence of 3M Co. as defendant, with its substantial litigation resources, may have accelerated commercial negotiations.
The complaint identified ‘3M Negative Pressure Wound Therapy Systems, such as the 3M Snap Therapy System’ as the accused products. The 3M Snap Therapy System is a portable, mechanically-powered NPWT device widely used in outpatient and home wound care settings. Both US8512301B2 and US9339595B2 were asserted against this product line.
No. The with-prejudice dismissal precludes TherapyPrimes from suing 3M and KCI USA again on these patents, but does not affect third-party NPWT manufacturers. US8512301B2 and US9339595B2 remain active and enforceable against other parties. Competitors in the compact or portable NPWT segment should independently assess their freedom-to-operate with respect to both patents.
PatSnap Eureka searches patents and litigation data to answer instantly.